title: Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications.
abstract: Osteopenia and osteoporosis are often long-term complications of anti-neoplastic treatments, defined as "cancer treatment-induced bone loss" (CTIBL). This pathological condition in oncologic patients results in a higher fracture risk than in the general population, and so has a significant negative impact on their quality of life. Hormone treatment is the main actor in this scenario, but not the only one. In fact, chemotherapies, radiotherapy and tyrosine kinase inhibitors may contribute to deregulate bone remodeling via different mechanisms. Thus, the identification of cancer patients at risk for CTIBL is essential for early diagnosis and appropriate intervention, that includes both lifestyle modifications and pharmacological approaches to prevent bone metabolism failure during anti-tumor treatments.
authors.affiliation: University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, Piazza Giulio Cesare, 11, 70124 Bari, Italy. Electronic address: ester86d@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: D'Oronzo
authors.affiliation: University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, Piazza Giulio Cesare, 11, 70124 Bari, Italy. Electronic address: stuccistefania@gmail.com.
authors.forename: S
authors.initials: S
authors.lastname: Stucci
authors.affiliation: University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, Piazza Giulio Cesare, 11, 70124 Bari, Italy. Electronic address: marco.tucci@uniba.it.
authors.forename: M
authors.initials: M
authors.lastname: Tucci
authors.affiliation: University of Bari "Aldo Moro", Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, Piazza Giulio Cesare, 11, 70124 Bari, Italy. Electronic address: francesco.silvestris@uniba.it.
authors.forename: F
authors.initials: F
authors.lastname: Silvestris
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D016723:Bone Remodeling / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D010024:Osteoporosis / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents
keywords: BMD; Bone loss; Cancer treatments; Osteoblast; Osteoclast